<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Surg</journal-id><journal-id journal-id-type="iso-abbrev">Front Surg</journal-id><journal-id journal-id-type="publisher-id">Front. Surg.</journal-id><journal-title-group><journal-title>Frontiers in Surgery</journal-title></journal-title-group><issn pub-type="epub">2296-875X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12098290</article-id><article-id pub-id-type="doi">10.3389/fsurg.2025.1592507</article-id><article-categories><subj-group subj-group-type="heading"><subject>Surgery</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Nomogram and scoring system for preoperative prediction of the risk of systemic inflammatory response syndrome in one-stage flexible ureteroscopy lithotripsy</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhou</surname><given-names>Yuan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="an1" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhang</surname><given-names>Haiyan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="an1" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Rentao</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Ding</surname><given-names>Yinman</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Zhengquan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lin</surname><given-names>Changming</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref><uri xlink:href="https://loop.frontiersin.org/people/2927712/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1"><label><sup>1</sup></label><institution>Department of Urology Surgery, The People&#x02019;s Hospital of Xuancheng City</institution>, <addr-line>Xuancheng</addr-line>, <country>China</country></aff><aff id="aff2"><label><sup>2</sup></label><institution>Wannan Medical College</institution>, <addr-line>Wuhu</addr-line>, <country>China</country></aff><aff id="aff3"><label><sup>3</sup></label><institution>Department of Urology Surgery, Huaian 82 Hospital</institution>, <addr-line>Huaian</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by"><p><bold>Edited by:</bold> Steffi Yuen, Prince of Wales Hospital, China</p></fn><fn fn-type="edited-by"><p><bold>Reviewed by:</bold> Huixia Zhou, Bayi Children's Hospital, China</p><p>Simone Morra, University of Naples Federico II, Italy</p></fn><corresp id="cor1"><label>*</label><bold>Correspondence:</bold> Changming Lin <email>changming_lin1971@163.com</email></corresp><fn fn-type="equal" id="an1"><label>
<sup>&#x02020;</sup>
</label><p>These authors share first authorship</p></fn></author-notes><pub-date pub-type="epub"><day>09</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>12</volume><elocation-id>1592507</elocation-id><history><date date-type="received"><day>12</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>22</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 Zhou, Zhang, Zhang, Ding, Wang and Lin.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Zhou, Zhang, Zhang, Ding, Wang and Lin</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec><title>Background</title><p>Flexible ureteroscopy lithotripsy (FURL) is a prevalent intervention for the management of upper urinary tract stones (UUTS). Assessing the onset of systemic inflammatory response syndrome (SIRS) in patients during and postoperatively is a critical determinant in the decision-making process regarding the necessity of preoperative ureteral stenting prior to FURL.</p></sec><sec><title>Materials and methods</title><p>A total of 340 patients with UUTS who underwent one-stage FURL were analyzed retrospectively. Least absolute shrinkage and selection operator and multivariate logistic regression analysis were used to screen out independent risk factors, subsequently developing a nomogram. The predictive performance was internally assessed using the concordance index (C-index), receiver operating characteristic curve, and calibration curve. Additionally, we evaluated the risk of SIRS in the context of one-stage FURL, considering the impact of various available variables.</p></sec><sec><title>Results</title><p>Age, urinary white blood cells, urine bacterial culture, and systemic immune-inflammation index (SII) were integrated to establish a nomogram for prediction of the risk of SIRS in patients undergoing one-stage FURL. The SII exhibited the highest odds ratio (OR&#x02009;=&#x02009;30.356) for SIRS. The nomogram demonstrated a favorable predictive performance with a C-index of 0.964 (95% CI&#x02009;=&#x02009;0.932&#x02013;0.996), an area under the curve of 0.935, and a calibration curve validating its accuracy. We further developed a scoring system and classified the risk of SIRS into four grades.</p></sec><sec><title>Conclusion</title><p>The developed nomogram and risk scoring system demonstrate favorable predictive ability and clinical serviceability for the personalized estimation of SIRS risk in UUTS patients undergoing one-stage FURL. It is advisable to place a ureteral stent prior to FURL in individuals with an SII exceeding 1,300 and meeting one of the following criteria: age&#x02009;&#x0003e;&#x02009;60 years, urinary white blood cell levels of 1+/2+/3+, or positive urine bacterial culture. The insights provided may assist clinicians in selecting safer therapeutic approaches for UUTS patients.</p></sec></abstract><kwd-group><kwd>ureteroscopy lithotripsy</kwd><kwd>upper urinary tract stone</kwd><kwd>systemic inflammatory response syndrome</kwd><kwd>nomogram</kwd><kwd>systemic immune-inflammation index</kwd><kwd>infection prevention</kwd></kwd-group><funding-group><funding-statement>The authors declare that no financial support was received for the research and/or publication of this article.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="4"/><equation-count count="0"/><ref-count count="31"/><page-count count="8"/><word-count count="0"/></counts><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Genitourinary Surgery and Interventions</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>Upper urinary tract stone (UUTS) is one of the most common diseases in urology, with an incidence rate of approximately 8.8% in the United States, and approximately 25% of patients with UUTS necessitate surgical intervention (<xref rid="B1" ref-type="bibr">1</xref>). Flexible ureteroscopy lithotripsy (FURL) is the preferred modality for managing UUTS measuring &#x0003c;2 cm in diameter, owing to its minimally invasive nature and expedited recovery compared with percutaneous nephrolithotomy (PCNL) and open surgical procedures (<xref rid="B2" ref-type="bibr">2</xref>). The standard treatment for FURL involves the initial placement of a ureteral stent, followed by lithotripsy in a subsequent stage. Preoperative insertion of a stent 2 weeks prior to FURL has been associated with reduced operative duration, improved stone-free rates, and lower complication rates compared with cases without ureteral stent placement (<xref rid="B3" ref-type="bibr">3</xref>). However, the two-stage FURL prolongs the hospitalization time and increases the economic burden on patients. Recently, one-stage FURL has demonstrated superior lithotripsy efficacy and has emerged as the preferred option among clinicians in practice (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>). Sepsis represents one of the most serious complications associated with FURL, with systemic inflammatory response syndrome (SIRS) identified as an early indicator of sepsis (<xref rid="B3" ref-type="bibr">3</xref>). Assessing SIRS development during and following FURL is a crucial factor in preoperative ureteral stent placement decision. Consequently, this study aimed to develop an effective prediction tool for assessing the risk of SIRS preoperatively in patients undergoing one-stage FURL based on the individual situation and routine laboratory results of UUTS patients.</p></sec><sec sec-type="methods" id="s2"><label>2</label><title>Materials and methods</title><sec id="s2a"><label>2.1</label><title>Study population</title><p>We conducted a retrospective analysis of patients diagnosed with UUTS who underwent one-stage FURL at the Department of Urology, Xuancheng People's Hospital, between July 2021 and May 2024. All patients presented with UUTS measuring &#x0003c;2.5&#x02005;cm in diameter and were deemed appropriate candidates for one-stage FURL intervention. Each procedure was performed under general anesthesia. We set the following inclusion criteria in this study: (a) all patients who had confirmed unilateral UUTC via computed tomography and (b) those over 18 years old and who did not have a nephrostomy tube or ureteral stent. The cohort consisted of individuals with unilateral UUTS, mainly ureteral calculi, with no infection beyond the urinary tract. We excluded individuals with significant cardiopulmonary impairment, coagulation abnormalities, or a history of psychiatric disorders, hematologic diseases, immunological disorders, splenic anomalies, and malignant neoplasms. None of the patients had received immunosuppressive agents, hormonal treatments, or antiplatelet medications in the past month. In addition, we excluded patients with solitary kidneys, polycystic kidney disease, horseshoe kidneys, uremia, or preoperative SIRS response. The study population did not include pregnant women or individuals who had undergone blood transfusions or experienced severe hemorrhage within the past year. All surgical procedures were performed by the same surgical team. In addition to the aforementioned exclusion criteria, no other patients who underwent one-stage FURL were excluded from the study.</p></sec><sec id="s2b"><label>2.2</label><title>Data acquisition</title><p>We obtained the available information of UUTS patients including age, gender, height, weight, stone site, stone size, diabetes, hydronephrosis, neutrophils, lymphocytes, platelets, blood creatinine, urinary white blood cells (WBC), urine bacterial culture, ureteral access sheath, and surgery time. For patients with urine WBC levels of 2+/3+ or positive urine cultures, a course of second-generation cephalosporin or sensitive antibiotic was administered for anti-inflammatory treatment 2 days before surgery. All patients received second-generation cephalosporin or sensitive antibiotic 30&#x02005;min before FURL to prevent the risk of infection. Mild hydronephrosis indicates a separation of the renal pelvis &#x0003c;2&#x02005;cm, whereas moderate or severe hydronephrosis is associated with a renal pelvis dilation exceeding 2&#x02005;cm. The body mass index (BMI) value is determined by an individual's height and weight measurements. The estimated glomerular filtration rate (EGFR) value is calculated based on the patient's gender, age, and is is is determined based on serum creatinine levels. The systemic immune-inflammation index (SII) is derived from the counts of blood neutrophils, lymphocytes, and platelets. A one-stage FURL signifies that patients underwent the procedure without prior placement of a ureteral stent. A two-stage FURL indicates that ureteral stenting was performed prior to the FURL. All patient examination information was preoperative results. SIRS positivity is defined as meeting at least two of the following criteria: body temperature exceeding 38.5&#x000b0;C or falling below 36&#x000b0;C; heart rate &#x0003e;90 beats per minute; respiratory rate exceeding 20 breaths per minute or PaCO<sub>2</sub> below 32&#x02005;mmHg; peripheral blood leukocyte count &#x0003e;12&#x02009;&#x000d7;&#x02009;10<sup>9</sup>/L or &#x0003c;4&#x02009;&#x000d7;&#x02009;10<sup>9</sup>/L; or the presence of immature granulocytes exceeding 10% (<xref rid="B2" ref-type="bibr">2</xref>). Postoperatively, all patients underwent hematological assessments, and respiratory and heart rates were monitored at least three times daily. If there was no SIRS response observed prior to discharge (typically 3 days postsurgery), the SIRS response was classified as negative.</p></sec><sec id="s2c"><label>2.3</label><title>Statistical analysis</title><p>The analysis encompassed various variables, including age, gender, BMI value, diabetes, stone site, stone size, hydronephrosis, urinary WBC, urine bacterial culture, EGFR value, SII value, ureteral access sheath, and surgery time. We used the least absolute shrinkage and selection operator (LASSO) regression to select predictive factors with non-zero coefficients. Subsequently, multivariate logistic regression analysis was conducted to isolate independent risk factors with a <italic>P</italic>-value of &#x0003c;0.05. Variance inflation factor (VIF) analysis was utilized to evaluate the collinearity information among the clinical variables and the final radiomics features. Combined with independent risk factors, we developed a nomogram to personalize the prediction of the risk of SIRS in one-stage FURL. The Hosmer&#x02013;Lemeshow test was performed to evaluate the goodness-of-fit of the nomogram. The predictive ability of the nomogram was internally evaluated by the receiver operating characteristic (ROC) curve and calibration curve. The concordance index (C-index) was measured to quantify the discrimination performance of the nonadherence nomogram. We used bootstrapping validation, comprising 1,000 bootstrap resamples, which was implemented for the non-adherence nomogram. Additionally, decision curve analysis (DCA) was conducted to test the clinical applicability of the non-adherence nomogram. This analysis was achieved by quantifying the net benefits at various threshold probabilities. The net benefit was computed as the proportion of true-positive patients minus the proportion of false-positive patients, while also taking into account the relative harm of not implementing an intervention as compared with the negative outcomes resulting from an unnecessary intervention. Utilizing the outcomes from each variable subgroup within the nomogram, we developed an SIRS scoring system through mathematical calculation. Subsequently, we divided the SIRS risk into four grades based on the scoring and patient population and compared the SIRS risk across varying grades. All statistical analyses and graphics were performed using R software (version 4.4.1), and a two-tailed <italic>P</italic>-value of &#x0003c;0.05 was deemed statistically significant.</p></sec></sec><sec sec-type="results" id="s3"><label>3</label><title>Results</title><sec id="s3a"><label>3.1</label><title>Patient data</title><p>A total of 340 UUTS patients who underwent one-stage FURL were selected in this study, of whom 31 (9.12%) developed SIRS. We compared age, gender, BMI value, diabetes, stone site, stone size, hydronephrosis, urinary WBC, urine bacterial culture, EGFR value, SII value, ureteral access sheath, and surgery time between the non-SIRS group and SIRS group. The baseline characteristics of both groups are listed in <xref rid="T1" ref-type="table">Table&#x000a0;1</xref>.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Baseline characteristics of the study cohort (<italic>n</italic>&#x02009;=&#x02009;340).</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="2" colspan="1">Characteristics</th><th valign="top" align="center" rowspan="1" colspan="1">Non-SIRS group (<italic>n</italic>&#x02009;=&#x02009;309)</th><th valign="top" align="center" rowspan="1" colspan="1">SIRS group (<italic>n</italic>&#x02009;=&#x02009;31)</th><th valign="top" align="center" rowspan="2" colspan="1"><italic>&#x003c7;</italic><sup>2</sup> value</th><th valign="top" align="center" rowspan="2" colspan="1"><italic>P</italic>-value</th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1"><italic>N</italic> (%)</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>N</italic> (%)</th></tr></thead><tbody><tr><td valign="top" align="left" colspan="3" rowspan="1">Gender</td><td valign="top" align="center" colspan="1" rowspan="1">6.200</td><td valign="top" align="center" colspan="1" rowspan="1">0.013</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male</td><td valign="top" align="center" rowspan="1" colspan="1">217 (70.23%)</td><td valign="top" align="center" rowspan="1" colspan="1">15 (48.39%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Female</td><td valign="top" align="center" rowspan="1" colspan="1">92 (29.77%)</td><td valign="top" align="center" rowspan="1" colspan="1">16 (51.61%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="3" rowspan="1">Age (years)</td><td valign="top" align="center" colspan="1" rowspan="1">3.679</td><td valign="top" align="center" colspan="1" rowspan="1">0.055</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02264;60</td><td valign="top" align="center" rowspan="1" colspan="1">261 (84.47%)</td><td valign="top" align="center" rowspan="1" colspan="1">22 (70.97%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;60</td><td valign="top" align="center" rowspan="1" colspan="1">48 (15.53%)</td><td valign="top" align="center" rowspan="1" colspan="1">9 (29.03%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="3" rowspan="1">Stone site</td><td valign="top" align="center" colspan="1" rowspan="1">3.825</td><td valign="top" align="center" colspan="1" rowspan="1">0.050</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Left</td><td valign="top" align="center" rowspan="1" colspan="1">173 (55.99%)</td><td valign="top" align="center" rowspan="1" colspan="1">23 (74.19%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Right</td><td valign="top" align="center" rowspan="1" colspan="1">136 (44.01%)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (25.81%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="3" rowspan="1">Stone size (cm)</td><td valign="top" align="center" colspan="1" rowspan="1">0.763</td><td valign="top" align="center" colspan="1" rowspan="1">0.382</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;0.8</td><td valign="top" align="center" rowspan="1" colspan="1">155 (50.16%)</td><td valign="top" align="center" rowspan="1" colspan="1">13 (41.94%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02265;0.8</td><td valign="top" align="center" rowspan="1" colspan="1">154 (49.84%)</td><td valign="top" align="center" rowspan="1" colspan="1">18 (58.06%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="3" rowspan="1">Ureteral access sheath</td><td valign="top" align="center" colspan="1" rowspan="1">0.295</td><td valign="top" align="center" colspan="1" rowspan="1">0.863</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">F10&#x02013;12</td><td valign="top" align="center" rowspan="1" colspan="1">89 (28.80%)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (25.81%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">F11&#x02013;13</td><td valign="top" align="center" rowspan="1" colspan="1">115 (37.22%)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (35.48%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">F12&#x02013;14</td><td valign="top" align="center" rowspan="1" colspan="1">105 (33.98%)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (38.71%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="3" rowspan="1">Hydronephrosis</td><td valign="top" align="center" colspan="1" rowspan="1">0.698</td><td valign="top" align="center" colspan="1" rowspan="1">0.404</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mild</td><td valign="top" align="center" rowspan="1" colspan="1">239 (77.35%)</td><td valign="top" align="center" rowspan="1" colspan="1">26 (83.87%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Moderate or severe</td><td valign="top" align="center" rowspan="1" colspan="1">70 (22.65%)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (16.13%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="3" rowspan="1">Urinary white blood cell</td><td valign="top" align="center" colspan="1" rowspan="1">79.226</td><td valign="top" align="center" colspan="1" rowspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">None or weakly positive</td><td valign="top" align="center" rowspan="1" colspan="1">200 (64.72%)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (22.58%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1+ or 2+</td><td valign="top" align="center" rowspan="1" colspan="1">95 (30.75%)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (25.81%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3+</td><td valign="top" align="center" rowspan="1" colspan="1">14 (4.53%)</td><td valign="top" align="center" rowspan="1" colspan="1">16 (51.61%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="3" rowspan="1">Urine bacterial culture</td><td valign="top" align="center" colspan="1" rowspan="1">57.741</td><td valign="top" align="center" colspan="1" rowspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">303 (98.06%)</td><td valign="top" align="center" rowspan="1" colspan="1">21 (67.74%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">6 (1.94%)</td><td valign="top" align="center" rowspan="1" colspan="1">10 (32.26%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="3" rowspan="1">Diabetes</td><td valign="top" align="center" colspan="1" rowspan="1">0.141</td><td valign="top" align="center" colspan="1" rowspan="1">0.708</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">None</td><td valign="top" align="center" rowspan="1" colspan="1">285 (92.23%)</td><td valign="top" align="center" rowspan="1" colspan="1">28 (90.32%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Yes</td><td valign="top" align="center" rowspan="1" colspan="1">24 (7.77%)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (9.68%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="3" rowspan="1">Surgery time (hours)</td><td valign="top" align="center" colspan="1" rowspan="1">5.268</td><td valign="top" align="center" colspan="1" rowspan="1">0.022</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;1</td><td valign="top" align="center" rowspan="1" colspan="1">267 (86.41%)</td><td valign="top" align="center" rowspan="1" colspan="1">22 (70.97%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02265;1</td><td valign="top" align="center" rowspan="1" colspan="1">42 (13.59%)</td><td valign="top" align="center" rowspan="1" colspan="1">9 (29.03%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="3" rowspan="1">BMI value (kg/m<sup>2</sup>)</td><td valign="top" align="center" colspan="1" rowspan="1">0.078</td><td valign="top" align="center" colspan="1" rowspan="1">0.780</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;22.9</td><td valign="top" align="center" rowspan="1" colspan="1">102 (33.01%)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (35.48%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02265;22.9</td><td valign="top" align="center" rowspan="1" colspan="1">207 (66.99%)</td><td valign="top" align="center" rowspan="1" colspan="1">20 (64.52%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="3" rowspan="1">EGFR (ml/min/1.73&#x02005;m<sup>2</sup>)</td><td valign="top" align="center" colspan="1" rowspan="1">2.397</td><td valign="top" align="center" colspan="1" rowspan="1">0.122</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;90</td><td valign="top" align="center" rowspan="1" colspan="1">125 (40.45%)</td><td valign="top" align="center" rowspan="1" colspan="1">17 (54.84%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02265;90</td><td valign="top" align="center" rowspan="1" colspan="1">184 (59.55%)</td><td valign="top" align="center" rowspan="1" colspan="1">14 (45.16%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="3" rowspan="1">SII value</td><td valign="top" align="center" colspan="1" rowspan="1">141.436</td><td valign="top" align="center" colspan="1" rowspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;700</td><td valign="top" align="center" rowspan="1" colspan="1">225 (72.82%)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (3.23%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">700&#x02013;1,300</td><td valign="top" align="center" rowspan="1" colspan="1">67 (21.68%)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (19.35%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;1,300</td><td valign="top" align="center" rowspan="1" colspan="1">17 (5.50%)</td><td valign="top" align="center" rowspan="1" colspan="1">24 (77.42%)</td><td valign="top" align="center" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="table-fn1"><p><italic>&#x003c7;</italic><sup>2</sup> is chi-square.</p></fn><fn id="table-fn2"><p>EGFR, estimated glomerular filtration rate; BMI, body mass index; SII, systemic immune-inflammation index.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><label>3.2</label><title>Independent risk factors</title><p>The feature selection of LASSO regression showed 13 features which were reduced to 6 potential predictors (<xref rid="F1" ref-type="fig">Figure&#x000a0;1</xref>), including age, stone site, hydronephrosis, urinary WBC, urine bacterial culture, and SII value. These non-zero coefficient predictors were subjected to further investigation through multivariate logistic regression analysis, and variables with <italic>P</italic>-values of &#x0003c;0.05 were considered independent risk factors. VIFs of the six radiomics features were tolerable (VIF value for variables: age&#x02009;=&#x02009;1.062, stone site&#x02009;=&#x02009;1.041, hydronephrosis&#x02009;=&#x02009;1.276, urinary white blood cell&#x02009;=&#x02009;1.228, urine bacterial culture&#x02009;=&#x02009;1.218, SII&#x02009;=&#x02009;1.129). The independent risk factors including age, urinary WBC, urine bacterial culture and SII value, and SII exhibited the highest odds ratio (OR) (value&#x02009;=&#x02009;30.356; 95% CI&#x02009;=&#x02009;10.215&#x02013;142.17) in relation to SIRS, followed by urine bacterial culture (<xref rid="T2" ref-type="table">Table&#x000a0;2</xref>).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>LASSO regression to screen out optimal parameter factors <bold>(A)</bold> and the relationship between each clinical variable and log (<italic>&#x003bb;</italic>) after parameter adjustment <bold>(B)</bold> in the LASSO model, 10-fold cross-validation was utilized to determine the optimal parameter <italic>&#x003bb;</italic> for the selection of radiomic features. At the optimal tuning parameter <italic>&#x003bb;</italic>&#x02009;=&#x02009;0.012 and log (<italic>&#x003bb;</italic>)&#x02009;=&#x02009;&#x02212;1.907, the dotted vertical lines were placed at the optimal values determined by the minimum criteria. A coefficient profile plot was created with respect to the log (<italic>&#x003bb;</italic>) sequence. The dotted vertical lines were drawn corresponding to the six non-zero coefficients, indicating the optimal value of <italic>&#x003bb;</italic> in the least absolute shrinkage and selection operator.</p></caption><graphic xlink:href="fsurg-12-1592507-g001" position="float"/></fig><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Multivariate logistic regression analysis of prediction factors for the study cohort.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Characteristics</th><th valign="top" align="center" rowspan="1" colspan="1">
<italic>&#x003b2;</italic>
</th><th valign="top" align="center" rowspan="1" colspan="1">SE</th><th valign="top" align="center" rowspan="1" colspan="1">Odds ratio (95% CI)</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age</td><td valign="top" align="center" rowspan="1" colspan="1">1.691</td><td valign="top" align="center" rowspan="1" colspan="1">0.760</td><td valign="top" align="center" rowspan="1" colspan="1">5.423 (1.253&#x02013;25.971)</td><td valign="top" align="center" rowspan="1" colspan="1">0.026</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stone site</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.787</td><td valign="top" align="center" rowspan="1" colspan="1">0.727</td><td valign="top" align="center" rowspan="1" colspan="1">0.455 (0.099&#x02013;1.796)</td><td valign="top" align="center" rowspan="1" colspan="1">0.279</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hydronephrosis</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;1.667</td><td valign="top" align="center" rowspan="1" colspan="1">1.119</td><td valign="top" align="center" rowspan="1" colspan="1">0.189 (0.016&#x02013;1.418)</td><td valign="top" align="center" rowspan="1" colspan="1">0.136</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Urinary white blood cell</td><td valign="top" align="center" rowspan="1" colspan="1">1.943</td><td valign="top" align="center" rowspan="1" colspan="1">0.502</td><td valign="top" align="center" rowspan="1" colspan="1">6.979 (2.853&#x02013;21.063)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Urine bacterial culture</td><td valign="top" align="center" rowspan="1" colspan="1">2.711</td><td valign="top" align="center" rowspan="1" colspan="1">1.278</td><td valign="top" align="center" rowspan="1" colspan="1">15.037 (1.456&#x02013;227.307)</td><td valign="top" align="center" rowspan="1" colspan="1">0.034</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SII</td><td valign="top" align="center" rowspan="1" colspan="1">3.413</td><td valign="top" align="center" rowspan="1" colspan="1">0.656</td><td valign="top" align="center" rowspan="1" colspan="1">30.356 (10.215&#x02013;142.17)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="table-fn3"><p><italic>&#x003b2;</italic> is the regression coefficient. SE is the standard error.</p></fn><fn id="table-fn4"><p>CI, confidence interval; SII, systemic immune-inflammation index.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c"><label>3.3</label><title>Establishment and validation nomogram</title><p>The independent risk factors, including age, urinary WBC, urine bacterial culture, and SII value, were integrated to develop a nomogram for individualized risk assessment of SIRS in patients undergoing one-stage FURL (<xref rid="F2" ref-type="fig">Figure&#x000a0;2</xref>). Calibration was evaluated using the Hosmer&#x02013;Lemeshow test with adaptive grouping (group&#x02009;=&#x02009;5), resulting in a chi-square statistic of 2.507 (<italic>P</italic>&#x02009;=&#x02009;0.474), which indicates no significant deviation between the predicted probabilities and observed outcomes, thereby suggesting robust calibration of the nomogram. The concordance index (C-index) was calculated at 0.964 (95% CI&#x02009;=&#x02009;0.932&#x02013;0.996), and the area under the curve (AUC) was determined to be 0.935, both nearing perfect performance. The calibration curves of the non-adherence nomogram indicated a favorable predictive capability for estimating the risk of SIRS in one-stage FURL (<xref rid="F3" ref-type="fig">Figure&#x000a0;3</xref>). The DCA curve showed a net benefit within almost all threshold probability ranges of patients in this study, demonstrating the clinical effectiveness of our prediction model (<xref rid="F4" ref-type="fig">Figure&#x000a0;4</xref>).</p><fig position="float" id="F2"><label>Figure 2</label><caption><p>Nomograms for preoperative prediction of the risk of SIRS in patients undergoing one-stage FURL.</p></caption><graphic xlink:href="fsurg-12-1592507-g002" position="float"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p>Receiver operating characteristic curve <bold>(A)</bold> and calibration curve <bold>(B)</bold> to internally verify the predictive accuracy of nomogram prediction.</p></caption><graphic xlink:href="fsurg-12-1592507-g003" position="float"/></fig><fig position="float" id="F4"><label>Figure 4</label><caption><p>Decision curve analysis to test the clinical serviceability of the nomogram.</p></caption><graphic xlink:href="fsurg-12-1592507-g004" position="float"/></fig></sec><sec id="s3d"><label>3.4</label><title>Risk scoring system for SIRS</title><p>By integrating the subgroup scores presented in the nomogram, we developed a risk scoring system to quantify the risk of SIRS for one-stage FURL. This risk scoring system was structured with a maximum of 100 points, wherein the higher score indicated a greater risk of SIRS occurrence in one-stage FURL (<xref rid="T3" ref-type="table">Table&#x000a0;3</xref>). The potential for SIRS development was classified into four grades, based on the subgroup scores and the number of patients with UUTC. The incidence and risk multiples for SIRS at each grade were shown in <xref rid="T4" ref-type="table">Table&#x000a0;4</xref>, indicating that 82.76% of patients classified in Grade IV developed SIRS, presenting a risk multiplier of 9.077 compared with the general cohort of UUTS patients (<xref rid="T4" ref-type="table">Table&#x000a0;4</xref>).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Scores of each subgroup in the risk scoring system.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="left" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Characteristics</th><th valign="top" align="center" rowspan="1" colspan="1">Points</th><th valign="top" align="center" rowspan="1" colspan="1">Characteristics</th><th valign="top" align="center" rowspan="1" colspan="1">Points</th></tr></thead><tbody><tr><td valign="top" align="left" colspan="1" rowspan="1">Age (years)</td><td valign="top" align="center" colspan="1" rowspan="1"/><td valign="top" align="left" colspan="1" rowspan="1">Urine bacterial culture</td><td valign="top" align="center" colspan="1" rowspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02264;60</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">Negative</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;60</td><td valign="top" align="center" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1">Positive</td><td valign="top" align="center" rowspan="1" colspan="1">17</td></tr><tr><td valign="top" align="left" colspan="1" rowspan="1">Urinary white blood cell</td><td valign="top" align="center" colspan="1" rowspan="1"/><td valign="top" align="left" colspan="1" rowspan="1">SII value</td><td valign="top" align="center" colspan="1" rowspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">None/weakly positive</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02264;700</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1+/2+</td><td valign="top" align="center" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">700&#x02013;1,300</td><td valign="top" align="center" rowspan="1" colspan="1">24</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3+</td><td valign="top" align="center" rowspan="1" colspan="1">26</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003e;1,300</td><td valign="top" align="center" rowspan="1" colspan="1">47</td></tr></tbody></table><table-wrap-foot><fn id="table-fn5"><p>SII, systemic immune-inflammation index.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>The comparison of each grade in the risk scoring system.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Grade</th><th valign="top" align="center" rowspan="1" colspan="1">Points</th><th valign="top" align="center" rowspan="1" colspan="1">Number (%)</th><th valign="top" align="center" rowspan="1" colspan="1">Number of patients with SIRS</th><th valign="top" align="center" rowspan="1" colspan="1">Incidence rate (%)</th><th valign="top" align="center" rowspan="1" colspan="1">Risk multiples</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">I</td><td valign="top" align="center" rowspan="1" colspan="1">0&#x02013;20</td><td valign="top" align="center" rowspan="1" colspan="1">202 (59.41%)</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0.50%</td><td valign="top" align="center" rowspan="1" colspan="1">0.054</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">II</td><td valign="top" align="center" rowspan="1" colspan="1">21&#x02013;40</td><td valign="top" align="center" rowspan="1" colspan="1">79 (23.24%)</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">1.267%</td><td valign="top" align="center" rowspan="1" colspan="1">0.134</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">III</td><td valign="top" align="center" rowspan="1" colspan="1">41&#x02013;55</td><td valign="top" align="center" rowspan="1" colspan="1">30 (8.82%)</td><td valign="top" align="center" rowspan="1" colspan="1">5</td><td valign="top" align="center" rowspan="1" colspan="1">16.67%</td><td valign="top" align="center" rowspan="1" colspan="1">1.828</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IV</td><td valign="top" align="center" rowspan="1" colspan="1">56&#x0223c;100</td><td valign="top" align="center" rowspan="1" colspan="1">29 (8.53%)</td><td valign="top" align="center" rowspan="1" colspan="1">24</td><td valign="top" align="center" rowspan="1" colspan="1">82.76%</td><td valign="top" align="center" rowspan="1" colspan="1">9.077</td></tr></tbody></table></table-wrap></sec></sec><sec sec-type="discussion" id="s4"><label>4</label><title>Discussion</title><p>Patients undergoing one-stage FULR exhibit an elevated incidence of SIRS compared with those receiving two-stage FULR (<xref rid="B3" ref-type="bibr">3</xref>). Indications for stent placement prior to FURL may include the presence of obstructive ureteral stones, calculus-induced pyelonephritis, patient-reported pain, or the need to facilitate the insertion of the flexible ureteroscope sheath (<xref rid="B3" ref-type="bibr">3</xref>). Our investigation encompassed 340 UUTS patients who received one-stage FURL, with 31 individuals (9.12%) developing SIRS. Previous research has indicated that the incidence of SIRS during and after FURL ranges from 6.7% to 20.7% (<xref rid="B6" ref-type="bibr">6</xref>). Sepsis represents the most severe complication associated with FURL, potentially resulting in septic shock and mortality (<xref rid="B7" ref-type="bibr">7</xref>). Levy et al. (<xref rid="B8" ref-type="bibr">8</xref>) compiled data on 25,375 sepsis patients, including 18,766 from the United States and 6,609 from Europe, reporting adjusted mortality rates of 32.3% and 31.3%, respectively. Therefore, urologists need to manage the risk of SIRS associated with FURL through general preoperative examinations and convenient tools.</p><p>In this study, we selected SIRS as an indicator to reflect urinary tract infections in UUTS patients. SIRS is a widely recognized biomarker of systemic inflammation and is recognized as an early manifestation of sepsis (<xref rid="B9" ref-type="bibr">9</xref>&#x02013;<xref rid="B11" ref-type="bibr">11</xref>). Some scholars have used other methodologies for the early prediction of sepsis, such as quick sequential organ failure assessment (qSOFA), which predicts sepsis risk based on changes in respiratory rate, systolic blood pressure, and mental status. However, its predictive validity has been suboptimal (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B13" ref-type="bibr">13</xref>). A statistical analysis conducted by Norwegian researchers on a cohort of 1,535 infected patients revealed that 108 had sepsis, yet only 33 (30.1%) satisfied the qSOFA criteria. Furthermore, among the 26 patients who died within 7 days, merely 4 (15.4%) exhibited a qSOFA score&#x02009;&#x02265;&#x02009;2 (<xref rid="B12" ref-type="bibr">12</xref>). Some other diseases may lead to false positives in the qSOFA assessment, such as cardiac embolism, respiratory distress syndrome, severe trauma, and anaphylactic shock. Due to the limited sensitivity of qSOFA to sepsis, international sepsis and septic shock management guidelines strongly advise against its use as a standalone screening instrument and emphasize that SIRS is more effective in assessing sepsis severity compared with qSOFA, blood lactate, and other biomarkers (<xref rid="B13" ref-type="bibr">13</xref>).</p><p>The variables in our study were derived from routine preoperative examinations of patients with UUTS, and the result showed that age, urinary WBC, urine bacterial culture, and SII value were identified as independent risk factors for the development of SIRS. In contrast to younger UUTS patients, older patients exhibited diminished immune functionality and a higher prevalence of potential diseases, thereby increasing their susceptibility to SIRS. In our analysis, a urine WBC 3+ was associated with a sensitivity of 0.53 and a specificity of 0.95 in predicting SIRS, while the sensitivity and specificity for SIRS prediction based on urine bacterial culture were found to be 0.63 and 0.94, respectively. Previous studies utilizing multiple logistic regression analysis had found that positivity for urine WBC, urine bacterial culture, and urine nitrite were independent risk factors for the onset of fever and SIRS in patients with UUTC (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B14" ref-type="bibr">14</xref>). Nitrite is usually not present in normal urine. Urinary bacteria, particularly gram-negative species, can convert nitrate into nitrite. In this study, only six patients exhibited nitrite positivity in their urine, which precluded its inclusion in the analysis. Our results showed that SII had the highest OR (30.356) for the development of SIRS in UUTS patients undergoing one-stage FURL. The sensitivity and specificity of predicting SIRS using urine SII&#x02009;&#x0003e;&#x02009;1,300 were found to be 0.59 and 0.98, respectively. Among the participants, five patients eventually progressed to sepsis, none died, and all patients with sepsis had an SII exceeding 1,300, with an average SII of 6,750.32. The SII has been proven to be a promising prognostic biomarker for evaluating the development of various inflammatory diseases and the prognosis of different malignancies (<xref rid="B15" ref-type="bibr">15</xref>&#x02013;<xref rid="B18" ref-type="bibr">18</xref>). Preoperative SII has also been demonstrated as a prognostic marker for evaluating infection risk in patients undergoing various surgeries, such as knee arthroplasty, cardiac stent implantation, and lung surgery (<xref rid="B19" ref-type="bibr">19</xref>&#x02013;<xref rid="B21" ref-type="bibr">21</xref>). Wang et al. (<xref rid="B22" ref-type="bibr">22</xref>) found that among the various predictive indicators for early severe mycoplasma pneumoniae pneumonia, the predictive capability of SII was significantly superior to that of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune response index, which demonstrates the superiority of SII as an innovative confirmatory predictor in reflecting systemic inflammation. In the field of urological lithotripsy, Peng et al. (<xref rid="B23" ref-type="bibr">23</xref>) investigated the role of preoperative SII in forecasting SIRS in PCNL and found that SII exhibited a superior predictive capacity than traditional inflammatory markers. Infectious UUTSs are more prone to SIRS response, where increased neutrophil counts and reduced lymphocyte levels may release pro-inflammatory mediators that could facilitate stone formation. Platelet activation can release vascular permeability factors by releasing 5-hydroxytryptamine from alpha particles and dense particles, which enhance vascular permeability, promote the chemotaxis of leukocytes, and participate in the inflammatory process (<xref rid="B23" ref-type="bibr">23</xref>). However, we have not found any studies focusing on preoperative SII as a predictor of infection in the context of FURL. Some other factors, such as pyuria and stone culture, have been verified to be related to the risk of SIRS in stone surgery (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). Nevertheless, the results of these indicators can only be obtained after surgery. The objective of this study was to preliminarily assess the SIRS associated with one-stage FURL through preoperative examination; hence, these indicators were not analyzed.</p><p>Nomogram, a statistical tool that graphically represents multiple independent risk factors, is widely utilized to assess the risk of disease incidence and prognosis (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>). In contrast to previous nomograms designed to predict SIRS risk in patients undergoing FURL (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>), our nomogram model exhibits several distinctions. Firstly, the cohort in this study comprised exclusively patients undergoing one-stage FURL. The focus of this study was to evaluate the risk of SIRS in UUTS patients who did not have ureteral stents placed prior to FURL, thereby enhancing the selection of surgical approaches in clinical practice. Secondly, we are the first to evaluate SII in relation to the development of SIRS in patients undergoing one-stage FURL. Thirdly, we developed a novel risk scoring system for predicting SIRS in one-stage FURL, categorizing the risk into four grades. Within our risk scoring system, SII&#x02009;&#x0003e;&#x02009;1,300 had the highest score of 47. Our risk scoring system showed Grade IV with points 55&#x02013;100, and the risk multiple for developing SIRS in Grade IV was 9.077 compared with the general population. We strongly advise that UUTS patients with a preoperative score of Grade IV should undergo a two-stage FURL procedure. Furthermore, we highly recommend that a ureteral stent should be placed prior to FURL in patients with SII&#x02009;&#x0003e;&#x02009;1,300 and one of the following criteria: age&#x02009;&#x0003e;&#x02009;60 years, urinary white blood cell levels of 1+/2+/3+, or positive urine bacterial culture (notably, approximately 80% of patients in this study developed SIRS).</p><p>However, there are still some limitations in our study. Firstly, the restricted sample size may introduce a potential bias in our results. Secondly, some variables, such as gender, diabetes, stone size, ureteral access sheath, and surgery time, did not demonstrate statistical significance in this study, but they have been recognized as influencing the risk of SIRS in existing literature (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>). Lastly, this study is a retrospective analysis conducted within a single medical institution and requires further prospective studies and external validation to corroborate our results.</p></sec><sec sec-type="conclusions" id="s5"><label>5</label><title>Conclusions</title><p>This study established a convenient nomogram incorporating age, urine WBC, urine bacterial culture, and SII value to preoperatively predict the risk of SIRS in patients undergoing one-stage FURL. Internal validation demonstrated that the nomogram has favorable predictive capability and clinical applicability. We are the first to introduce a risk scoring system for SIRS in patients undergoing one-stage FURL, identifying SII as the most relevant risk factor. We strongly recommend the placement of a ureteral stent prior to FURL in patients with SII&#x02009;&#x0003e;&#x02009;1,300 and meeting one of the following: age&#x02009;&#x0003e;&#x02009;60 years, urinary white blood cell levels of 1+/2+/3+, or positive urine bacterial culture. These novel insights may assist clinicians in selecting safer therapeutic approaches for UUTS patients.</p></sec></body><back><fn-group><title>Abbreviations</title><fn fn-type="abbr" id="ab001"><p>UUTS, upper urinary tract stone; FURL, flexible ureteroscopy lithotripsy; PCNL, percutaneous nephrolithotomy; SIRS, systemic inflammatory response syndrome; WBC, urinary white blood cells; BMI, body mass index; EGFR, estimated glomerular filtration rate; SII, systemic immune-inflammation index; LASSO, least absolute shrinkage and selection operator; VIF, variance inflation factor; C-index, concordance index; ROC, receiver operating characteristic; DCA, decision curve analysis; OR, odds ratio; CI, confidence interval; qSOFA, quick sequential organ failure assessment.</p></fn></fn-group><sec sec-type="data-availability" id="s6"><title>Data availability statement</title><p>The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.</p></sec><sec sec-type="ethics-statement" id="s7"><title>Ethics statement</title><p>The studies involving humans were approved by the Ethics Review Office of Xuancheng People's Hospital (No. AF-SOP-29-1). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.</p></sec><sec sec-type="author-contributions" id="s8"><title>Author contributions</title><p>YZ: Data curation, Formal analysis, Writing &#x02013; original draft. HZ: Data curation, Formal analysis, Writing &#x02013; original draft. RZ: Data curation, Validation, Writing &#x02013; original draft. YD: Investigation, Project administration, Writing &#x02013; original draft. ZW: Data curation, Writing &#x02013; original draft. CL: Conceptualization, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="s10"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s11"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s12"><title>Publisher's note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>YC</given-names></name><name><surname>Jian</surname><given-names>ZY</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name></person-group>. <article-title>Preoperative urine nitrite versus urine culture for predicting postoperative fever following flexible ureteroscopic lithotripsy: a propensity score matching analysis</article-title>. <source>World J Urol</source>. (<year>2021</year>) <volume>39</volume>(<issue>3</issue>):<fpage>897</fpage>&#x02013;<lpage>905</lpage>. <pub-id pub-id-type="doi">10.1007/s00345-020-03240-w</pub-id><pub-id pub-id-type="pmid">32430571</pub-id>
</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>YY</given-names></name><name><surname>Huo</surname><given-names>YJ</given-names></name><name><surname>Xia</surname><given-names>SJ</given-names></name><name><surname>Shao</surname><given-names>Y</given-names></name></person-group>. <article-title>Systemic inflammatory response syndrome combined with pre- and postoperative white blood cell ratio is a better criterion to identify septic shock patients after flexible ureteroscopic lithotripsy</article-title>. <source>J Endourol</source>. (<year>2021</year>) <volume>35</volume>(<issue>7</issue>):<fpage>973</fpage>&#x02013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1089/end.2020.1002</pub-id><pub-id pub-id-type="pmid">33218256</pub-id>
</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Assimos</surname><given-names>D</given-names></name><name><surname>Crisci</surname><given-names>A</given-names></name><name><surname>Culkin</surname><given-names>D</given-names></name><name><surname>Xue</surname><given-names>W</given-names></name><name><surname>Roelofs</surname><given-names>A</given-names></name><name><surname>Duvdevani</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Preoperative JJ stent placement in ureteric and renal stone treatment: results from the Clinical Research Office of Endourological Society (CROES) ureteroscopy (URS) global study</article-title>. <source>BJU Int</source>. (<year>2016</year>) <volume>117</volume>(<issue>4</issue>):<fpage>648</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1111/bju.13250</pub-id><pub-id pub-id-type="pmid">26237735</pub-id>
</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>WN</given-names></name><name><surname>Huang</surname><given-names>HL</given-names></name><name><surname>Wang</surname><given-names>YH</given-names></name><name><surname>Chen</surname><given-names>WX</given-names></name><name><surname>Deng</surname><given-names>H</given-names></name><name><surname>Zhong</surname><given-names>MZ</given-names></name></person-group>. <article-title>Application of 11/13Fr suctioning ureteral access sheath and 8.55Fr single-use digital flexible ureteroscope in one-stage flexible ureteroscopic lithotripsy: an initial experience of 900 cases</article-title>. <source>Urolithiasis</source>. (<year>2024</year>) <volume>52</volume>(<issue>1</issue>):<fpage>112</fpage>. <pub-id pub-id-type="doi">10.1007/s00240-024-01607-x</pub-id><pub-id pub-id-type="pmid">39105853</pub-id>
</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>HL</given-names></name><name><surname>Jin</surname><given-names>XX</given-names></name><name><surname>Zhu</surname><given-names>YX</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name></person-group>. <article-title>The feasibility of one-stage flexible ureteroscopy lithotripsy in solitary kidney patients with 1&#x02013;3&#x02005;cm renal stones and risk factors of renal function changes</article-title>. <source>Ren Fail</source>. (<year>2021</year>) <volume>43</volume>(<issue>1</issue>):<fpage>264</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1080/0886022X.2021.1872625</pub-id><pub-id pub-id-type="pmid">33491554</pub-id>
</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mi</surname><given-names>QW</given-names></name><name><surname>Meng</surname><given-names>XJ</given-names></name><name><surname>Meng</surname><given-names>LH</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Fang</surname><given-names>SW</given-names></name></person-group>. <article-title>Risk factors for systemic inflammatory response syndrome induced by flexible ureteroscope combined with holmium laser lithotripsy</article-title>. <source>Biomed Res Int</source>. (<year>2020</year>) <volume>2020</volume>:<fpage>6842479</fpage>. <pub-id pub-id-type="doi">10.1155/2020/6842479</pub-id><pub-id pub-id-type="pmid">32280696</pub-id>
</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>LB</given-names></name><name><surname>Yu</surname><given-names>XZ</given-names></name><name><surname>Qiu</surname><given-names>ZZ</given-names></name><name><surname>Liu</surname><given-names>PY</given-names></name><name><surname>Tian</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>Influence of preoperative urine culture and bacterial species on urogenital sepsis after ureteral flexible lithotripsy in patients with upper urinary tract stones</article-title>. <source>Front Med (Lausanne)</source>. (<year>2024</year>) <volume>11</volume>:<fpage>1393734</fpage>. <pub-id pub-id-type="doi">10.3389/fmed.2024.1393734</pub-id><pub-id pub-id-type="pmid">38765255</pub-id>
</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>M</given-names></name><name><surname>Artigas</surname><given-names>A</given-names></name><name><surname>Phillips</surname><given-names>G</given-names></name><name><surname>Rhodes</surname><given-names>A</given-names></name><name><surname>Beale</surname><given-names>R</given-names></name><name><surname>Osborn</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study</article-title>. <source>Lancet Infect Dis</source>. (<year>2012</year>) <volume>12</volume>(<issue>12</issue>):<fpage>919</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(12)70239-6</pub-id><pub-id pub-id-type="pmid">23103175</pub-id>
</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schefzik</surname><given-names>R</given-names></name><name><surname>Hahn</surname><given-names>B</given-names></name><name><surname>Schneider</surname><given-names>LV</given-names></name></person-group>. <article-title>Dissecting contributions of individual systemic inflammatory response syndrome criteria from a prospective algorithm to the prediction and diagnosis of sepsis in a polytrauma cohort</article-title>. <source>Front Med (Lausanne)</source>. (<year>2023</year>) <volume>31</volume>(<issue>10</issue>):<fpage>1227031</fpage>. <pub-id pub-id-type="doi">10.3389/fmed.2023.1227031</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>JJ</given-names></name><name><surname>Hu</surname><given-names>XD</given-names></name><name><surname>Wang</surname><given-names>ZW</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Gan</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>MW</given-names></name><etal/></person-group>
<article-title>The role of mtDAMPs in the trauma-induced systemic inflammatory response syndrome</article-title>. <source>Front Immunol</source>. (<year>2023</year>) <volume>18</volume>(<issue>14</issue>):<fpage>1164187</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2023.1164187</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>WJ</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Jin</surname><given-names>TT</given-names></name><name><surname>Lu</surname><given-names>TY</given-names></name><name><surname>Zhou</surname><given-names>FH</given-names></name></person-group>. <article-title>Progress in the study of biomarkers for early prediction of systemic inflammatory response syndrome after percutaneous nephrolithotomy</article-title>. <source>Front Immunol</source>. (<year>2023</year>) <volume>30</volume>(<issue>14</issue>):<fpage>1142346</fpage>. <pub-id pub-id-type="doi">10.3389/fmed.2023.1227031</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Askim</surname><given-names>A</given-names></name><name><surname>Moser</surname><given-names>F</given-names></name><name><surname>Gustad</surname><given-names>L</given-names></name><name><surname>Stene</surname><given-names>H</given-names></name><name><surname>Gundersen</surname><given-names>M</given-names></name><name><surname>&#x000c5;svold</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Poor performance of quick-SOFA (qSOFA) score in predicting severe sepsis and mortality&#x02014;a prospective study of patients admitted with infection to the emergency department</article-title>. <source>Scand J Trauma Resusc Emerg Med</source>. (<year>2017</year>) <volume>25</volume>(<issue>1</issue>):<fpage>56</fpage>. <pub-id pub-id-type="doi">10.1186/s13049-017-0399-4</pub-id><pub-id pub-id-type="pmid">28599661</pub-id>
</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>L</given-names></name><name><surname>Rhodes</surname><given-names>A</given-names></name><name><surname>Alhazzani</surname><given-names>W</given-names></name><name><surname>Antonelli</surname><given-names>M</given-names></name><name><surname>Coopersmith</surname><given-names>CM</given-names></name><name><surname>French</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021</article-title>. <source>Intensive Care Med</source>. (<year>2021</year>) <volume>47</volume>(<issue>11</issue>):<fpage>1181</fpage>&#x02013;<lpage>247</lpage>. <pub-id pub-id-type="doi">10.1097/CCM.0000000000005337</pub-id><pub-id pub-id-type="pmid">34599691</pub-id>
</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>SK</given-names></name><name><surname>Zhang</surname><given-names>YY</given-names></name><name><surname>Zeng</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>WZ</given-names></name><etal/></person-group>
<article-title>Enhanced antibiotic treatment based on positive urine dipstick infection test before percutaneous nephrolithotomy did not prevent postoperative infection in patients with negative urine culture</article-title>. <source>J Endourol</source>. (<year>2021</year>) <volume>35</volume>(<issue>12</issue>):<fpage>1743</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1089/end.2021.0185</pub-id><pub-id pub-id-type="pmid">34002622</pub-id>
</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pricop</surname><given-names>M</given-names></name><name><surname>Ancusa</surname><given-names>O</given-names></name><name><surname>Talpos</surname><given-names>S</given-names></name><name><surname>Urechescu</surname><given-names>H</given-names></name><name><surname>Bumbu</surname><given-names>BA</given-names></name></person-group>. <article-title>The predictive value of systemic immune-inflammation index and symptom severity score for sepsis and systemic inflammatory response syndrome in odontogenic infections</article-title>. <source>J Pers Med</source>. (<year>2022</year>) <volume>12</volume>(<issue>12</issue>):<fpage>2026</fpage>. <pub-id pub-id-type="doi">10.3390/jpm12122026</pub-id><pub-id pub-id-type="pmid">36556246</pub-id>
</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staniewska</surname><given-names>E</given-names></name><name><surname>Grudzien</surname><given-names>K</given-names></name><name><surname>Stankiewicz</surname><given-names>M</given-names></name><name><surname>Raczek</surname><given-names>ZK</given-names></name><name><surname>Rembak</surname><given-names>SJ</given-names></name><name><surname>Nowicka</surname><given-names>Z</given-names></name><etal/></person-group>
<article-title>The prognostic value of the systemic immune-inflammation index (SII) and red cell distribution width (RDW) in patients with cervical cancer treated using radiotherapy</article-title>. <source>Cancers (Basel)</source>. (<year>2024</year>) <volume>16</volume>(<issue>8</issue>):<fpage>1542</fpage>. <pub-id pub-id-type="doi">10.3390/cancers16081542</pub-id><pub-id pub-id-type="pmid">38672624</pub-id>
</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>WC</given-names></name><name><surname>Song</surname><given-names>YC</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>HS</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>You</surname><given-names>QQ</given-names></name><etal/></person-group>
<article-title>Systemic immune-inflammation index is associated with diabetic kidney disease in type 2 diabetes mellitus patients: evidence from NHANES 2011&#x02013;2018</article-title>. <source>Front Endocrinol (Lausanne)</source>. (<year>2022</year>) <volume>6</volume>(<issue>13</issue>):<fpage>1071465</fpage>. <pub-id pub-id-type="doi">10.3389/fendo.2022.1071465</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>HS</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>YF</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name></person-group>. <article-title>The systemic immune-inflammation index as an independent predictor of survival in patients with locally advanced esophageal squamous cell carcinoma undergoing neoadjuvant radiotherapy</article-title>. <source>J Inflamm Res</source>. (<year>2024</year>) <volume>11</volume>(<issue>17</issue>):<fpage>4575</fpage>&#x02013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.2147/JIR.S463163</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Telang</surname><given-names>S</given-names></name><name><surname>Mayfield</surname><given-names>CK</given-names></name><name><surname>Palmer</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>KC</given-names></name><name><surname>Wier</surname><given-names>J</given-names></name><name><surname>Hong</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Preoperative laboratory values predicting periprosthetic joint infection in morbidly obese patients undergoing total hip or knee arthroplasty</article-title>. <source>J Bone Joint Surg Am</source>. (<year>2024</year>) <volume>106</volume>(<issue>14</issue>):<fpage>1317</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.2106/JBJS.23.01360</pub-id><pub-id pub-id-type="pmid">38941451</pub-id>
</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>PP</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Ren</surname><given-names>RQ</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Hao</surname><given-names>PP</given-names></name><etal/></person-group>
<article-title>Usefulness of the systemic inflammation response Index and the systemic immune inflammation index in predicting restenosis after stent implantation</article-title>. <source>J Inflamm Res</source>. (<year>2024</year>) <volume>23</volume>(<issue>17</issue>):<fpage>4941</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.2147/JIR.S461277</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>HH</given-names></name><name><surname>Ge</surname><given-names>DY</given-names></name><name><surname>Wang</surname><given-names>QW</given-names></name><name><surname>Zhou</surname><given-names>LL</given-names></name><name><surname>Chen</surname><given-names>HS</given-names></name><name><surname>Qin</surname><given-names>YB</given-names></name><etal/></person-group>
<article-title>Predictive significance of systemic immune-inflammation index combined with prealbumin for postoperative pneumonia following lung resection surgery</article-title>. <source>BMC Pulm Med</source>. (<year>2024</year>) <volume>24</volume>(<issue>1</issue>):<fpage>277</fpage>. <pub-id pub-id-type="doi">10.1186/s12890-024-03086-7</pub-id><pub-id pub-id-type="pmid">38862955</pub-id>
</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>SY</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>WB</given-names></name></person-group>. <article-title>The clinical value of systemic immune inflammation index (SII) in predicting the severity of hospitalized children with Mycoplasma Pneumoniae pneumonia: a retrospective study</article-title>. <source>Int J Gen Med</source>. (<year>2024</year>) <volume>17</volume>:<fpage>935</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.2147/IJGM.S451466</pub-id><pub-id pub-id-type="pmid">38495920</pub-id>
</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>JL</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>JJ</given-names></name><name><surname>Pan</surname><given-names>SH</given-names></name></person-group>. <article-title>Significance of preoperative systemic immune-inflammation (SII) in predicting postoperative systemic inflammatory response syndrome after percutaneous nephrolithotomy</article-title>. <source>Urolithiasis</source>. (<year>2021</year>) <volume>49</volume>(<issue>6</issue>):<fpage>513</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s00240-021-01266-2</pub-id><pub-id pub-id-type="pmid">33835228</pub-id>
</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Jiang</surname><given-names>CH</given-names></name><name><surname>Liang</surname><given-names>XF</given-names></name><name><surname>Zhong</surname><given-names>FL</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>YP</given-names></name><etal/></person-group>
<article-title>Early and rapid prediction of postoperative infections following percutaneous nephrolithotomy in patients with complex kidney stones</article-title>. <source>BJU Int</source>. (<year>2019</year>) <volume>123</volume>(<issue>6</issue>):<fpage>1041</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/bju.14484</pub-id><pub-id pub-id-type="pmid">30007112</pub-id>
</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benson</surname><given-names>AD</given-names></name><name><surname>Juliano</surname><given-names>TM</given-names></name><name><surname>Miller</surname><given-names>NL</given-names></name></person-group>. <article-title>Infectious outcomes of nephrostomy drainage before percutaneous nephrolithotomy compared with concurrent access</article-title>. <source>J Urol</source>. (<year>2014</year>) <volume>192</volume>(<issue>3</issue>):<fpage>770</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.juro.2014.03.004</pub-id><pub-id pub-id-type="pmid">24631102</pub-id>
</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leon</surname><given-names>MD</given-names></name><name><surname>Lundsberg</surname><given-names>LS</given-names></name><name><surname>Culhane</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Son</surname><given-names>M</given-names></name><name><surname>Reddy</surname><given-names>UM</given-names></name></person-group>. <article-title>Fetal growth restriction and small for gestational age as predictors of neonatal morbidity: which growth nomogram to use?</article-title>
<source>Am J Obstet Gynecol</source>. (<year>2023</year>) <volume>229</volume>(<issue>6</issue>):<fpage>678</fpage>. <pub-id pub-id-type="doi">10.1016/j.ajog.2023.06.035</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>CM</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>RT</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>YY</given-names></name></person-group>. <article-title>Nomograms and scoring system for forecasting overall and cancer-specific survival of patients with prostate cancer</article-title>. <source>Cancer Med</source>. (<year>2023</year>) <volume>12</volume>(<issue>3</issue>):<fpage>2600</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1002/cam4.5137</pub-id><pub-id pub-id-type="pmid">35993499</pub-id>
</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>JX</given-names></name><name><surname>Xu</surname><given-names>JZ</given-names></name><name><surname>Liu</surname><given-names>CQ</given-names></name><name><surname>Xun</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>JL</given-names></name><name><surname>Xu</surname><given-names>MY</given-names></name></person-group>. <article-title>A novel nomogram for predicting post-operative sepsis for patients with solitary, unilateral and proximal ureteral stones after treatment using percutaneous nephrolithotomy or flexible ureteroscopy</article-title>. <source>Front Surg</source>. (<year>2022</year>) <volume>15</volume>(<issue>9</issue>):<fpage>814293</fpage>. <pub-id pub-id-type="doi">10.3389/fsurg.2022.814293</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xuan</surname><given-names>ZJ</given-names></name><name><surname>Yu</surname><given-names>ZK</given-names></name><name><surname>Tan</surname><given-names>GB</given-names></name><name><surname>Ding</surname><given-names>N</given-names></name><name><surname>He</surname><given-names>HB</given-names></name><name><surname>Yu</surname><given-names>SC</given-names></name><etal/></person-group>
<article-title>Development and validation of a novel nomogram for predicting systemic inflammatory response syndrome&#x02019;s occurrence in patients undertaking flexible ureteroscopy</article-title>. <source>Transl Androl Urol</source>. (<year>2022</year>) <volume>11</volume>(<issue>2</issue>):<fpage>228</fpage>&#x02013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.21037/tau-22-34</pub-id><pub-id pub-id-type="pmid">35280653</pub-id>
</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giulioni</surname><given-names>C</given-names></name><name><surname>Brocca</surname><given-names>C</given-names></name><name><surname>Gauhar</surname><given-names>V</given-names></name><name><surname>Somani</surname><given-names>BK</given-names></name><name><surname>Chew</surname><given-names>BH</given-names></name><name><surname>Traxe</surname><given-names>O</given-names></name><etal/></person-group>
<article-title>Does age impact outcomes of retrograde intrarenal surgery in the elderly? Results from 366 patients from the FLEXible ureteroscopy outcomes registry (FLEXOR)</article-title>. <source>Aging Clin Exp Res</source>. (<year>2023</year>) <volume>35</volume>(<issue>11</issue>):<fpage>2711</fpage>&#x02013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1007/s40520-023-02545-1</pub-id><pub-id pub-id-type="pmid">37682489</pub-id>
</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohanty</surname><given-names>S</given-names></name><name><surname>Kamolvit</surname><given-names>W</given-names></name><name><surname>Scheffschick</surname><given-names>A</given-names></name><name><surname>Bj&#x000f6;rklund</surname><given-names>A</given-names></name><name><surname>Tovi</surname><given-names>J</given-names></name><name><surname>Espinosa</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Diabetes downregulates the antimicrobial peptide psoriasin and increases E. coli burden in the urinary bladder</article-title>. <source>Nat Commun</source>. (<year>2022</year>) <volume>13</volume>(<issue>1</issue>):<fpage>4983</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-022-32636-y</pub-id><pub-id pub-id-type="pmid">36127330</pub-id>
</mixed-citation></ref></ref-list></back></article>